Immunovant (IMVT) Non Operating Income (2018 - 2026)

Immunovant has reported Non Operating Income for 9 years, with the latest figure at $798000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 25.49% year-over-year to $798000.0; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 364.04% YoY), and the FY2026 full-year result was $2.2 million, up 363.06% from the prior year.
• Non Operating Income for Q1 2026 stood at $798000.0, up from -$54000.0 in the prior quarter.
• The five-year high for Non Operating Income was $1.2 million in Q2 2025, with the low at -$2.6 million in Q1 2024.
• Historically, Non Operating Income has averaged $84235.3 across 5 years, with a median of $354000.0 in 2022.
• Annual changes were most pronounced in 2022 — Non Operating Income plunged 1441.23% — and 2025, when it soared 4139.29%.
• Immunovant's Non Operating Income stood at -$1.8 million in 2022, then jumped by 162.27% to $1.1 million in 2023, then slumped by 214.99% to -$1.3 million in 2024, then jumped by 95.71% to -$54000.0 in 2025, then jumped by 1577.78% to $798000.0 in 2026.
• The last three Non Operating Income figures came in at $798000.0 (Q1 2026), -$54000.0 (Q4 2025), and $250000.0 (Q3 2025), per Business Quant data.